{"hands_on_practices": [{"introduction": "A cornerstone of medical genetics is the ability to provide accurate genetic counseling, which requires a firm grasp of Mendelian inheritance. This first exercise [@problem_id:5042486] provides practice in this essential skill by focusing on an X-linked recessive form of Glycogen Storage Disease. By working from first principles, you will determine the specific risks for male and female offspring, reinforcing your understanding of how sex chromosomes influence inheritance patterns and disease manifestation.", "problem": "A couple seeks counseling about Glycogen Storage Disease (GSD) IX due to a known pathogenic variant in the phosphorylase kinase alpha 2 (*PHKA2*) gene in the mother. *PHKA2*-related GSD IX is inherited in an X-linked recessive (XLR) manner. The mother is a confirmed heterozygous carrier of a pathogenic *PHKA2* variant, and the father is clinically unaffected and has tested negative for *PHKA2* pathogenic variants. Assume the following foundational principles:\n- Mendelian segregation applies, with equal segregation of alleles during gametogenesis.\n- Sex determination follows the standard model in humans: sons inherit the $Y$ chromosome from the father and the single maternal $X$, whereas daughters inherit one $X$ chromosome from each parent.\n- The sex ratio at birth is $1:1$.\n- Penetrance is complete in hemizygous males with the pathogenic *PHKA2* variant; heterozygous females are not considered clinically affected for the purpose of this calculation.\n- The probability of de novo mutation and germline mosaicism is negligible.\n\nUsing these principles, derive from first principles the probability that a future son will be affected with *PHKA2*-related GSD IX and the probability that a future daughter will be affected. Express each probability as an exact fraction (no rounding). Report your final result as a row matrix with entries in the order $\\big(P(\\text{affected son}),\\,P(\\text{affected daughter})\\big)$.", "solution": "We begin from Mendelian and chromosomal principles. For an X-linked gene such as *PHKA2*, males are hemizygous ($XY$) and possess a single $X$ chromosome inherited from the mother, while females are typically heterozygous or homozygous at X-linked loci as they inherit two $X$ chromosomes (one from each parent).\n\nGiven:\n- The mother is heterozygous for a pathogenic *PHKA2* variant, so her two $X$ chromosomes can be denoted as $X^{\\ast}$ (pathogenic) and $X$ (non-pathogenic).\n- The father is unaffected and has a normal $X$ chromosome and a $Y$ chromosome, denoted $X$ and $Y$.\n\nFoundational rules:\n- By Mendel’s first law (law of segregation), the mother transmits $X^{\\ast}$ with probability $\\frac{1}{2}$ and $X$ with probability $\\frac{1}{2}$ to each child.\n- For sons, the paternal contribution is necessarily $Y$, and for daughters, the paternal contribution is necessarily $X$.\n- The sex ratio is $1:1$, but because the problem asks for the probability conditional on the child being a son versus a daughter, we compute conditional probabilities for each sex.\n\nCompute the risk for a son:\n- A son inherits $Y$ from the father and one $X$ from the mother. The probability the son inherits $X^{\\ast}$ from the mother is $\\frac{1}{2}$.\n- A male who inherits $X^{\\ast}$ is hemizygous for the pathogenic variant and, under the assumption of complete penetrance in hemizygous males, will be affected.\n- Therefore, the probability that a future son is affected is\n$$\nP(\\text{affected son}) \\;=\\; \\frac{1}{2}.\n$$\n\nCompute the risk for a daughter:\n- A daughter inherits the father’s normal $X$ and one maternal $X$. With probability $\\frac{1}{2}$ she inherits $X^{\\ast}$ and becomes a heterozygous carrier ($X^{\\ast}X$), and with probability $\\frac{1}{2}$ she inherits the maternal normal $X$ and is $XX$.\n- Under X-linked recessive inheritance with an unaffected father and the stated assumption that heterozygous females are not considered clinically affected for this calculation, daughters will not be affected because they always receive a normal $X$ from the unaffected father.\n- Therefore, the probability that a future daughter is affected is\n$$\nP(\\text{affected daughter}) \\;=\\; 0.\n$$\n\nThus, the requested row matrix in the specified order $\\big(P(\\text{affected son}),\\,P(\\text{affected daughter})\\big)$ is\n$$\n\\begin{pmatrix}\n\\frac{1}{2} & 0\n\\end{pmatrix}.\n$$", "answer": "$$\\boxed{\\begin{pmatrix}\\frac{1}{2} & 0\\end{pmatrix}}$$", "id": "5042486"}, {"introduction": "Moving from the scale of a single family to an entire population requires the tools of population genetics. This problem [@problem_id:5042470] introduces the Hardy-Weinberg principle, a fundamental concept for estimating the frequency of carriers for autosomal recessive disorders. You will learn how to use the observable incidence of a disease, such as a GSD, to calculate the \"hidden\" frequency of heterozygous carriers in a population, a critical metric for public health planning and genetic screening.", "problem": "A particular glycogen storage disease (GSD) is inherited as an autosomal recessive trait caused by biallelic pathogenic variants at a single locus with two alleles, wild-type $A$ and pathogenic $a$. Consider a large, randomly mating population in Hardy–Weinberg equilibrium (HWE), with no selection, mutation, migration, or genetic drift, and complete penetrance. Let the allele frequencies of $A$ and $a$ be $p$ and $q$, respectively, with $p+q=1$. The observed incidence of clinically affected individuals (genotype $aa$) in this population is $q^{2} = \\frac{1}{100{,}000}$.\n\nStarting from the definitions of allele and genotype frequencies under HWE, derive the expected carrier (heterozygous $Aa$) frequency in terms of $q$, and then compute its numerical value using the given incidence. Express your final answer as a decimal fraction, rounded to four significant figures.", "solution": "The frequencies of the three genotypes—homozygous wild-type ($AA$), heterozygous ($Aa$), and homozygous pathogenic ($aa$)—are described by the terms of the binomial expansion of $(p+q)^2$:\n- Frequency of genotype $AA$ is $p^2$.\n- Frequency of genotype $Aa$ is $2pq$.\n- Frequency of genotype $aa$ is $q^2$.\n\nThe sum of these genotype frequencies must equal $1$: $p^2 + 2pq + q^2 = (p+q)^2 = 1^2 = 1$.\n\nCarriers of the disease are heterozygous individuals with the genotype $Aa$. Therefore, the carrier frequency is the frequency of the $Aa$ genotype, which is $2pq$.\n\nThe problem requires the derivation of this carrier frequency in terms of the allele frequency $q$. We use the relation $p = 1 - q$ and substitute it into the expression for the carrier frequency:\n$$\n\\text{Carrier Frequency} = 2pq = 2(1-q)q = 2q - 2q^2\n$$\nNext, we are asked to compute the numerical value of the carrier frequency. The problem provides the incidence of clinically affected individuals (genotype $aa$) as:\n$$\nq^2 = \\frac{1}{100,000} = 1 \\times 10^{-5} = 0.00001\n$$\nFrom this, we can find the frequency of the pathogenic allele, $q$, by taking the square root:\n$$\nq = \\sqrt{q^2} = \\sqrt{1 \\times 10^{-5}} = \\sqrt{0.00001}\n$$\nNow, we substitute the values of $q$ and $q^2$ into the derived expression for the carrier frequency:\n$$\n\\text{Carrier Frequency} = 2q - 2q^2 = 2\\sqrt{0.00001} - 2(0.00001)\n$$\nPerforming the numerical calculation:\n$$\nq = \\sqrt{0.00001} \\approx 0.00316227766\n$$\nThe carrier frequency is calculated as:\n$$\n\\text{Carrier Frequency} \\approx 2(0.00316227766) - 2(0.00001) = 0.00632455532 - 0.00002 = 0.00630455532\n$$\nThe problem specifies that the final answer should be expressed as a decimal fraction rounded to four significant figures. The calculated value is approximately $0.00630455532$. The first significant figure is $6$, the second is $3$, the third is $0$, and the fourth is $4$. The fifth significant figure is $5$, which requires rounding up the fourth digit.\n$$\n0.00630455532 \\approx 0.006305\n$$\nThus, the expected carrier frequency is $0.006305$.", "answer": "$$\\boxed{0.006305}$$", "id": "5042470"}, {"introduction": "This final practice exercise [@problem_id:5042442] simulates a complex, real-world challenge in modern medicine: designing and evaluating a newborn screening program. You will analyze how benign genetic variants, known as pseudodeficiency alleles, can significantly impact the performance of a screening test by creating false positives and reducing its predictive value. This case study demonstrates why sophisticated, multi-tier testing strategies that integrate biochemical assays with molecular genotyping are essential for achieving both high sensitivity and high specificity in population-wide screening.", "problem": "A state newborn screening program measures acid alpha-glucosidase (GAA) activity in dried blood spots to identify infants with Pompe disease (Glycogen Storage Disease type II). Use the following foundational base:\n\n- The Central Dogma of Molecular Biology states that deoxyribonucleic acid (DNA) variants can alter ribonucleic acid (RNA) and protein sequences, thus changing enzyme kinetics and measured activity. A pseudodeficiency allele is a DNA variant that reduces measured enzyme activity in the assay without producing clinical disease, because the in vivo lysosomal function remains sufficient.\n\n- Diagnostic test characteristics are defined as follows. Sensitivity is the probability of a positive test given disease. Specificity is the probability of a negative test given no disease. The positive predictive value (PPV) is the probability of disease given a positive test. Let $Se$ denote sensitivity, $Sp$ denote specificity, and $p$ denote disease prevalence.\n\nIn a population of $N = 200000$ newborns, the prevalence of Pompe disease is $p = \\frac{1}{40000}$. The first-tier enzymatic screen has sensitivity $Se_{1} = 0.99$. Among truly non-diseased newborns without pseudodeficiency, the first-tier specificity is $Sp_{1} = 0.995$. However, pseudodeficiency alleles in the acid alpha-glucosidase (*GAA*) gene (for example, `c.1726G>A` producing `p.Gly576Ser` and `c.2065G>A` producing `p.Glu689Lys`) occur at frequency $q = 0.02$ in this population and cause first-tier positive results with probability approximately $1.00$ despite absence of disease.\n\nThe program is considering a two-tier approach: retain the first-tier enzymatic screen, then reflex second-line *GAA* genotyping that identifies common pseudodeficiency alleles and known pathogenic variants. Assume the second-tier genotyping detects pathogenic variants in truly affected infants with sensitivity $Se_{g} = 0.98$ and very rarely misclassifies a non-diseased infant as carrying a pathogenic variant, with a false positive probability of $0.001$ among first-tier false positives. Assume second-tier genotyping identifies pseudodeficiency alleles with sensitivity effectively $1.00$ and uses this information to classify those first-tier positives as screen negative. A screen is called positive only if both tiers are positive and genotyping does not reveal a pseudodeficiency-only genotype.\n\nWhich option best explains how pseudodeficiency alleles impact first-tier screening specificity and PPV, and correctly proposes the two-tier approach’s impact on overall sensitivity, specificity, and PPV under the assumptions above?\n\nA. Pseudodeficiency alleles inflate false positives among non-diseased infants, lowering overall first-tier specificity from $Sp_{1}$ to $Sp_{\\text{with pseudo}} = 1 - \\left[q + (1-q)(1-Sp_{1})\\right] = 0.9751$. In $N = 200000$, expected first-tier true positives are $N p Se_{1} = 5 \\times 0.99 = 4.95$, while false positives are $N(1-p)\\left[q + (1-q)(1-Sp_{1})\\right] \\approx 199995 \\times 0.0249 \\approx 4980$, yielding a first-tier PPV of approximately $\\frac{4.95}{4.95 + 4980} \\approx 0.000993$. A two-tier algorithm with reflex GAA genotyping (detecting pathogenic variants with $Se_{g} = 0.98$, classifying pseudodeficiency-only genotypes as negative, and misclassifying $0.001$ of first-tier false positives as pathogenic) yields overall sensitivity $Se_{\\text{overall}} = Se_{1} \\times Se_{g} = 0.9702$, false positives reduced to $\\approx 4980 \\times 0.001 = 4.98$, overall specificity $\\approx \\frac{199995 - 4.98}{199995} \\approx 0.999975$, and PPV $\\approx \\frac{4.95 \\times 0.98}{(4.95 \\times 0.98) + 4.98} \\approx 0.493$.\n\nB. Pseudodeficiency alleles primarily reduce sensitivity by causing true Pompe disease cases to test negative, so the first-tier sensitivity drops from $0.99$ to $0.975$, while specificity stays near $0.995$. Adding second-tier genotyping does not change specificity but increases sensitivity to approximately $0.995$; PPV rises modestly to $\\approx 0.02$.\n\nC. Pseudodeficiency alleles are best managed by raising the first-tier activity threshold, which both increases specificity from $0.995$ to $0.999$ and leaves sensitivity unchanged at $0.99$. This single-tier adjustment increases PPV to approximately $0.80$ in the given population without requiring genotyping.\n\nD. Pseudodeficiency alleles create false positives, but repeating the same first-tier enzyme assay as a second step (without genotyping) will remove almost all of them. With a repeat test, specificity improves to approximately $0.995$ and PPV to approximately $\\frac{0.99 \\times \\frac{1}{40000}}{0.99 \\times \\frac{1}{40000} + 0.005 \\times \\left(1 - \\frac{1}{40000}\\right)} \\approx 0.165$, with no change in sensitivity.", "solution": "The solution proceeds in two main parts: first, an analysis of the single-tier screening system, and second, an analysis of the proposed two-tier system.\n\n**Part 1: Analysis of the First-Tier Enzymatic Screen**\n\nThe problem provides the following parameters:\n- Population size: $N = 200000$\n- Disease prevalence: $p = P(D^+) = \\frac{1}{40000} = 0.000025$\n- Probability of not having the disease: $P(D^-) = 1 - p = \\frac{39999}{40000} = 0.999975$\n- First-tier sensitivity: $Se_{1} = P(T_1^+ | D^+) = 0.99$\n- Specificity in non-diseased individuals without pseudodeficiency: $Sp_{1} = P(T_1^- | D^-, \\neg Ps) = 0.995$. The false positive rate in this subgroup is $1 - Sp_1 = 0.005$.\n- Proportion of non-diseased individuals with pseudodeficiency: $P(Ps | D^-) = q = 0.02$. Consequently, the proportion of non-diseased without pseudodeficiency is $P(\\neg Ps | D^-) = 1 - q = 0.98$.\n- Probability of a positive test for non-diseased individuals with pseudodeficiency: $P(T_1^+ | D^-, Ps) = 1.00$.\n\nFirst, we must calculate the overall specificity of the first-tier screen, which is compromised by the pseudodeficiency alleles. The overall false positive rate, $P(T_1^+ | D^-)$, is calculated using the law of total probability, conditioning on the presence of pseudodeficiency ($Ps$):\n$$P(T_1^+ | D^-) = P(T_1^+ | D^-, Ps) P(Ps | D^-) + P(T_1^+ | D^-, \\neg Ps) P(\\neg Ps | D^-)$$\n$$P(T_1^+ | D^-) = (1.00)(0.02) + (1 - 0.995)(1 - 0.02)$$\n$$P(T_1^+ | D^-) = 0.02 + (0.005)(0.98) = 0.02 + 0.0049 = 0.0249$$\nThe overall specificity for the first-tier screen, $Sp_{\\text{with pseudo}}$, is therefore:\n$$Sp_{\\text{with pseudo}} = 1 - P(T_1^+ | D^-) = 1 - 0.0249 = 0.9751$$\nThis confirms the first part of the statement in option A, which states that pseudodeficiency alleles lower the specificity to $Sp_{\\text{with pseudo}} = 1 - \\left[q + (1-q)(1-Sp_{1})\\right] = 1 - [0.02 + (0.98)(0.005)] = 0.9751$.\n\nNext, we calculate the expected number of true positives (TP) and false positives (FP) in the population of $N=200000$ newborns for the first tier.\n- Number of diseased individuals: $N \\times p = 200000 \\times \\frac{1}{40000} = 5$.\n- Number of non-diseased individuals: $N \\times (1-p) = 200000 - 5 = 199995$.\n- Expected first-tier true positives: $TP_1 = (\\text{Number diseased}) \\times Se_1 = 5 \\times 0.99 = 4.95$.\n- Expected first-tier false positives: $FP_1 = (\\text{Number non-diseased}) \\times P(T_1^+|D^-) = 199995 \\times 0.0249 \\approx 4979.8755 \\approx 4980$.\n\nUsing these values, we calculate the first-tier Positive Predictive Value ($PPV_1$):\n$$PPV_1 = \\frac{TP_1}{TP_1 + FP_1} \\approx \\frac{4.95}{4.95 + 4980} = \\frac{4.95}{5029.95} \\approx 0.0009841$$\nThe calculation in option A yields $\\frac{4.95}{4.95 + 4980} \\approx 0.000993$. The minor difference arises from using the rounded FP value of $4980$. Using the unrounded FP value $4979.8755$ gives $\\frac{4.95}{4.95 + 4979.8755} = \\frac{4.95}{4984.8255} \\approx 0.0009930$. The result is consistent.\n\n**Part 2: Analysis of the Two-Tier Screening Approach**\n\nThe two-tier approach adds a second-line genotyping test for all first-tier positives. The parameters for the second tier are:\n- Sensitivity of genotyping for pathogenic variants in affected infants: $Se_g = 0.98$.\n- Genotyping identifies pseudodeficiency-only cases with sensitivity $\\approx 1.00$, and these are classified as screen negative.\n- The probability of a second-tier test misclassifying a first-tier false positive as pathogenic is $0.001$.\n\nFirst, we calculate the overall sensitivity, $Se_{\\text{overall}}$. An affected individual must test positive on both tiers.\n$$Se_{\\text{overall}} = P(T_1^+ \\text{ and } T_2^+ | D^+) = P(T_2^+ | T_1^+, D^+) \\times P(T_1^+ | D^+)$$\nAssuming the genotyping sensitivity $Se_g$ applies to the true positives from the first tier:\n$$Se_{\\text{overall}} = Se_g \\times Se_1 = 0.98 \\times 0.99 = 0.9702$$\nThe expected number of overall true positives is $TP_{\\text{overall}} = (\\text{Number diseased}) \\times Se_{\\text{overall}} = 5 \\times 0.9702 = 4.851$. This is equivalent to taking the first-tier true positives, $4.95$, and multiplying by $Se_g$: $4.95 \\times 0.98 = 4.851$.\n\nNext, we calculate the overall false positives, $FP_{\\text{overall}}$.\nThe initial number of first-tier false positives is $FP_1 \\approx 4980$. These individuals undergo second-tier testing. The problem states that individuals with pseudodeficiency-only genotypes are identified and classified as negative. The final false positives arise from the misclassification of first-tier false positives as pathogenic, which occurs with a probability of $0.001$.\n$$FP_{\\text{overall}} = FP_1 \\times 0.001 \\approx 4980 \\times 0.001 = 4.98$$\nThis simplification implies that after correctly excluding all pseudodeficiency cases, the remaining first-tier false positives (those due to the $1-Sp_1$ error) and any other potential error source in the second tier result in a net $0.1\\%$ false positive rate for the second tier among all first-tier false positives.\n\nThe overall specificity, $Sp_{\\text{overall}}$, is the proportion of non-diseased individuals who test negative overall.\nNumber of true negatives overall = (Total non-diseased) - $FP_{\\text{overall}}$\n$$(\\text{TN}_{\\text{overall}}) = 199995 - 4.98 = 199990.02$$\n$$Sp_{\\text{overall}} = \\frac{\\text{TN}_{\\text{overall}}}{\\text{Total non-diseased}} = \\frac{199990.02}{199995} \\approx 0.999975099... \\approx 0.999975$$\n\nFinally, we calculate the overall Positive Predictive Value, $PPV_{\\text{overall}}$:\n$$PPV_{\\text{overall}} = \\frac{TP_{\\text{overall}}}{TP_{\\text{overall}} + FP_{\\text{overall}}} \\approx \\frac{4.851}{4.851 + 4.98} = \\frac{4.851}{9.831} \\approx 0.4934$$\n\n**Evaluation of Options**\n\n**A. Pseudodeficiency alleles inflate false positives among non-diseased infants, lowering overall first-tier specificity from $Sp_{1}$ to $Sp_{\\text{with pseudo}} = 1 - \\left[q + (1-q)(1-Sp_{1})\\right] = 0.9751$. In $N = 200000$, expected first-tier true positives are $N p Se_{1} = 5 \\times 0.99 = 4.95$, while false positives are $N(1-p)\\left[q + (1-q)(1-Sp_{1})\\right] \\approx 199995 \\times 0.0249 \\approx 4980$, yielding a first-tier PPV of approximately $\\frac{4.95}{4.95 + 4980} \\approx 0.000993$. A two-tier algorithm with reflex GAA genotyping (detecting pathogenic variants with $Se_{g} = 0.98$, classifying pseudodeficiency-only genotypes as negative, and misclassifying $0.001$ of first-tier false positives as pathogenic) yields overall sensitivity $Se_{\\text{overall}} = Se_{1} \\times Se_{g} = 0.9702$, false positives reduced to $\\approx 4980 \\times 0.001 = 4.98$, overall specificity $\\approx \\frac{199995 - 4.98}{199995} \\approx 0.999975$, and PPV $\\approx \\frac{4.95 \\times 0.98}{(4.95 \\times 0.98) + 4.98} \\approx 0.493$.**\n\nThis option correctly identifies that pseudodeficiency alleles create false positives and lower specificity. The calculation for the new specificity ($0.9751$) is correct. The calculation of first-tier TP ($4.95$) and FP ($\\approx 4980$) is correct. The first-tier PPV calculation ($\\approx 0.000993$) is correct. The calculation of overall sensitivity for the two-tier system ($0.9702$) is correct. The calculation of the reduced number of false positives ($\\approx 4.98$) is correct based on the problem's assumption. The calculation for overall specificity ($\\approx 0.999975$) is correct. The final PPV calculation ($\\approx 0.493$) is also correct. Every statement and calculation in this option aligns with our derivation.\n**Verdict: Correct.**\n\n**B. Pseudodeficiency alleles primarily reduce sensitivity by causing true Pompe disease cases to test negative, so the first-tier sensitivity drops from $0.99$ to $0.975$, while specificity stays near $0.995$. Adding second-tier genotyping does not change specificity but increases sensitivity to approximately $0.995$; PPV rises modestly to $\\approx 0.02$.**\n\nThis option is fundamentally flawed. Pseudodeficiency is defined as affecting non-diseased individuals, causing false positives by mimicking the disease state in an assay. It impacts specificity, not sensitivity. The claim that it reduces sensitivity is incorrect. Consequently, all subsequent calculations and conclusions based on this faulty premise are invalid.\n**Verdict: Incorrect.**\n\n**C. Pseudodeficiency alleles are best managed by raising the first-tier activity threshold, which both increases specificity from $0.995$ to $0.999$ and leaves sensitivity unchanged at $0.99$. This single-tier adjustment increases PPV to approximately $0.80$ in the given population without requiring genotyping.**\n\nThis option is scientifically implausible. In any diagnostic test, there is an inherent trade-off between sensitivity and specificity (visualized by an ROC curve). It is generally not possible to significantly increase specificity (from $0.995$ to $0.999$) without a corresponding decrease in sensitivity. The claim that sensitivity remains unchanged at $0.99$ violates this principle. Furthermore, pseudodeficiency variants often cause enzyme activity levels that are very low and overlap with the activity levels of true disease, making separation by a simple threshold adjustment difficult or impossible.\n**Verdict: Incorrect.**\n\n**D. Pseudodeficiency alleles create false positives, but repeating the same first-tier enzyme assay as a second step (without genotyping) will remove almost all of them. With a repeat test, specificity improves to approximately $0.995$ and PPV to approximately $\\frac{0.99 \\times \\frac{1}{40000}}{0.99 \\times \\frac{1}{40000} + 0.005 \\times \\left(1 - \\frac{1}{40000}\\right)} \\approx 0.165$, with no change in sensitivity.**\n\nThis option proposes an ineffective strategy. Pseudodeficiency is a biological, systematic cause of low enzyme activity in the assay, not a random analytical error. An individual with such a genotype will consistently test positive on the same enzymatic assay. Repeating the test will not \"remove\" these false positives. The calculation presented is also flawed, as it uses a false positive rate of $0.005$, which corresponds to the specificity *without* pseudodeficiency ($1-0.995$), completely ignoring the dominant contribution of pseudodeficiency alleles ($q=0.02$) to the false positive rate.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "5042442"}]}